Latest Research, Industry, Medical and Scientific News
For a chronic health condition that causes shame and misery for countless people and costs billions, urinary incontinence keeps a low profile. Media reports about chronic health conditions appear with alarming regularity, but it is rare to read about the debilitating impact of the involuntary leakage of urine. Nevertheless, urinary incontinence is a condition which, next to Alzheimer’s or strokes, is reported as most negatively affecting “health-related quality of life”. The reasons for this are not too hard to fathom. Urinary incontinence, of course, elicits some embarrassment. And there also seems to be a feeling this is a low priority condition: urinary incontinence does not directly bear up against the terrible impacts of life threatening conditions and illnesses. Read more.
Source: The Conversation, February 14, 2018
Scientists from the University of Sheffield have developed a material that could be used as an alternative to the current vaginal mesh material, polypropylene, used to treat pelvic organ prolapse and stress urinary incontinence. The use of these current meshes, in particular surgical procedures, has led to severe complications for millions of women across the world and is now banned in Australia. The research conducted by the University of Sheffield, published today in the journal Neurourology and Urodynamics, provides evidence which supports the use of a softer and more elastic material better suited for use in the pelvic floor and one that releases oestrogen into the surrounding pelvic tissue to form new blood vessels and ultimately speed up the healing process. Read more.
Source: EurekAlert, February 13, 2018
Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced that the human clinical trial for the patented formulation in its product UriVarx® product for bladder health was published in the peer reviewed journal, BMC Complementary and Alternative Medicine (Schoendorfer et al. BMC Complementary and Alternative Medicine (2018) 18:42). The study was conducted by the team of Dr. Niikee Schoendorfer in Australia in collaboration with the Company’s UriVarx® licensing partner Seipel Group, Ltd. The outcome of this study demonstrated both statistical significance and clinical relevance in reducing symptoms of Overactive Bladder (“OAB”), urinary frequency and/or urgency and incontinence. Read more.
Source: Digital Journal, February 7, 2018
New Zealand’s regulatory body Medsafe has taken steps to remove a number of surgical mesh products from the country, according to a release posted today. The agency said the product’s removal was the outcome of a recent regulatory action on surgical mesh products, specifically those designed for treating pelvic organ prolapse via transvaginal implantation and one mini-sling product designed to treat stress urinary incontinence. Medsafe said that last December it requested safety information from four surgical mesh suppliers in New Zealand, following action taken by Australia’s TGA as it looked to review meshes used for urogynaecological use. The earlier TGA’s investigation ended in regulatory actions to remove the devices from the market, MedSafe said, and similarly resulted in their removal from New Zealand’s market. Read more.
Source: +Mass Device, January 31, 2018
It may seem like undergoing surgery to have a child wouldn’t have a lot of advantages, but it turns out there may be some benefits to having a cesarean section. Experts warn, however, that it doesn’t mean you should schedule the operation unless it’s needed. A study in PLOS Medicine concluded that women who have cesarean deliveries (also known as C-sections) have a lower risk of urinary incontinence and pelvic prolapse. Dr. Sarah Stock, who researches preterm birth at the University of Edinburgh in Scotland, and her team looked at one randomized controlled trial and 79 cohort studies involving nearly 30 million women. The studies looked at long-term outcomes of women who had the surgery compared to those who delivered vaginally. Read more.
Source: Healthline, January 23, 2018
Urinary incontinence (UI), the involuntary leakage of urine, is a frequent and problematic chronic condition for many patients. An estimated 10 to 30% of men and women are affected nationally, though this may be underestimated due to underdiagnoses and undertreatment.1-3 Often, patients who suffer with UI symptoms will develop poor self-rated health, depression, and mobility disability.4,5 This comorbid disease state also presents a substantial financial burden; data from 2014 found that in the United States alone, an estimated $65.9 billion in direct and indirect costs were spent for UI treatment.3 Read more.
Source: Drug Topics, January 23, 2018